Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on May 14, 2020, regarding an event that occurred on May 13, 2020. The filing discloses the entry into a material definitive agreement for a private placement of equity securities.
Key Financial Metrics
The filing details a specific capital raise transaction rather than periodic financial performance metrics.
- Transaction Type: Sale of Common Stock
- Investor: Lincoln Park Capital Fund, LLC
- Shares Issued: 1,000,000 shares
- Price Per Share: $1.09
- Aggregate Purchase Price: $1,090,000
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is an event-driven report, not a financial statement.
Material Changes
The primary material change is the execution of a Purchase Agreement on May 13, 2020. This transaction was conducted pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-236735), which was declared effective on March 19, 2020.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard legal disclosures associated with the equity offering. The transaction was executed under the Securities Act of 1933, as amended.
Investor Verification Checklist
- Verify the final closing of the $1,090,000 transaction with Lincoln Park Capital Fund, LLC.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for any covenants or restrictions on the Company.
- Confirm the impact of the 1,000,000 new shares on existing shareholder dilution.
- Check subsequent filings for the actual receipt of proceeds and updated cash position.